Provider
Vasomotor Symptoms - Commercial
Prior Authorization, Quantity Limit
Program effective Date: Apr 01, 2026
Documents & Forms Results
Displaying 3581 - 3590 of 3636 results
Provider
Xolair (omalizumab) - Commercial
Prior Authorization
Program effective Date: Apr 01, 2026
Provider
Interstitial Lung Disease - Commercial
Prior Authorization, Quantity Limit
Program effective Date: Apr 01, 2026
Provider
Multiple Sclerosis Agents - Commercial
Step Therapy, Quantity Limit
Program effective Date: Apr 01, 2026
Provider
Opioids ER - Commercial
Prior Authorization, Quantity Limit
Program effective Date: Apr 01, 2026
Provider
Oral NSAID (Nonsteroidal Anti-Inflammatory Drugs) - Commercial
Step Therapy
Program effective Date: Apr 01, 2026
Provider
Opioids Immediate Release (IR) New To Therapy with Daily Quantity Limit - Commercial
Quantity Limit
Program effective Date: Apr 01, 2026
Provider
Attention Deficit [Hyperactivity] Disorder (ADHD/ADD) Agents - Commercial
Quantity Limit
Program effective Date: Apr 01, 2026
Provider
Zeposia (ozanimod) - Medicaid
Prior Authorization, Quantity Limit
Program effective Date: Apr 01, 2026
Provider
Xolair (omalizumab) - Medicaid
Prior Authorization
Program effective Date: Apr 01, 2026